Enjoy complimentary customisation on priority with our Enterprise License!
The global autoinjectors market size is estimated to grow/decline by USD 303.65 billion at a CAGR of 36.72% between 2023 and 2028. Market growth hinges on several factors, notably the escalating prevalence of allergies necessitating prompt care. The burgeoning popularity of injectable therapies further propels this growth trajectory, offering effective treatment options. Additionally, the surge in commercial approvals of new products amplifies market expansion, signaling a dynamic landscape of innovation and accessibility. Allergies, ranging from common irritants to severe reactions, drive the demand for swift and reliable interventions, fostering a conducive environment for market growth. The increasing awareness and acceptance of injectable treatments underscore a shift towards efficacious and convenient solutions, aligning with consumer preferences. Moreover, the continuous influx of novel products entering the market broadens treatment options, catering to diverse patient needs and reinforcing the upward trajectory of the allergy treatment market.
To learn more about this report, Download Report Sample
In market segmentation, the landscape is shaped by various factors including loss of exclusivity in biologics, which prompts the need for innovative solutions. Needle phobia and the risk of anaphylactic shocks drive demand for user-friendly devices. Autoinjectors, equipped with syringes for precise drug delivery, cater to healthcare professionals and providers addressing diverse needs. The prominence of adrenaline in treating anaphylaxis underscores the critical role of autoinjectors in emergency conditions. Additionally, autoinjectors facilitate self-administration, particularly for chronic disorders, offering convenience and empowerment to patients. With advancements like Bluetooth connectivity enhancing connectivity and monitoring capabilities, autoinjectors redefine conventional drug delivery methods. The market's segmentation reflects a dynamic interplay of technology, healthcare demands, and patient-centric solutions, positioning autoinjectors as indispensable tools in modern therapy.
The market share growth by the anaphylaxis segment will be significant during the forecast period. The anaphylaxis segment generates the highest revenue because of the increasing prevalence of anaphylaxis and food allergies at a global level. For instance, according to the Centers for Disease Control and Prevention (CDC), around 8% of children in the US have food allergies.
Get a glance at the market contribution of various segments Download PDF Sample
The anaphylaxis segment was valued at USD 24.6 billion in 2018. Anaphylaxis is an acute, potentially fatal condition that is often a response to an allergen. One of the most effective treatments for anaphylaxis is the intramuscular administration of epinephrine, and it is the first line of treatment drugs. There are many auto-injector suppliers in the global market that offer epinephrine auto-injectors specifically for anaphylaxis. Therefore, the availability in the market of auto-injectors that enable self-administration of anaphylaxis medications and vendor support in demonstrating the process of self-administration are expected to propel this segment, making it the global automotive market.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. Canada is witnessing an increase in healthcare spending that will further propel the North American market during the forecast period. The Brazilian auto-injector market is expected to grow during the forecast period, owing to the country's economic growth, improved access to remote medical facilities, and rising awareness of auto-injectors in the country. The high prevalence of anaphylaxis in the United States leads to high adoption of generic epinephrine auto-injectors. With the availability of the generic EpiPen, a product of Mylan, at affordable price points, the sales volume of epinephrine autoinjectors is expected to increase in the US market, boosting the market growth.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
AbbVie Inc., Amgen Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., RAVIMED Sp. zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed Holding AG
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is driven by various factors such as the loss of exclusivity for conventional drug delivery methods, increasing adoption of biologics, and the rising prevalence of chronic disorders. Needle phobia and the need for rapid response in emergency conditions fuel demand for needle-free injectors like the EpiPen autoinjector, addressing concerns around anaphylactic shocks. Challenges include ensuring healthcare professionals and patients are adept at using autoinjectors, and addressing concerns about Bluetooth connectivity for data monitoring. Despite challenges, autoinjectors offer promising solutions for self-administering therapy, enhancing patient convenience and treatment efficacy. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of allergies and need for immediate care is the key factor driving the growth of the market. Globally, the prevalence of allergies to food items, pollens, food additives, latex, and dust and the risk of contracting anaphylaxis caused by these factors are increasing. According to CDC, allergies are the sixth leading cause of chronic illness in the US, with an annual expenditure of more than USD 18 billion. More than 50 million North Americans are affected by allergies each year. On average, 30%-35% of the global population is diagnosed with an allergy annually. Canada is witnessing an increase in healthcare spending that will further propel the North American market during the forecast period.
Further, the Brazilian market is expected to grow during the forecast period, owing to the country's economic growth, improved access to remote medical facilities, and rising awareness of auto-injectors in the country. The high prevalence of anaphylaxis in the United States leads to high adoption of generic epinephrine auto-injectors. Autoinjectors can treat symptoms with a small dose of epinephrine. These autoinjectors help restore normal breathing, increase blood pressure if it is dropping, and reduce swelling. With the increasing occurrence of allergies, the growth prospects of epinephrine autoinjectors are likely to rise, as they can be self-administered during sudden anaphylactic attacks. Therefore, the increasing prevalence of allergies and the need for immediate care will boost the growth of the market during the forecast period.
Strategic alliances between companies is the primary trend in the market. Strategic alliances in the market are on the rise, with several acquisitions/partnerships aimed at expanding the business by offering new mineral cosmetics. For instance, Pfizer Inc. works in association with Antares Pharma to develop an autoinjector pen for an undisclosed Pfizer drug. Pfizer product utilizes Antares Pharma patented QuickShot autoinjector and an unrevealed drug.
Moreover, Pfizer Inc. will obtain US FDA approval and marketing permission for interferons in the coming years. The development agreement between Antares Pharma and Pfizer aims to expand the portfolio of pipeline partners' products. Further, such strategic alliances will help Pfizer Inc. increase the potential number of products utilizing Antares Pharma innovative QuickShot autoinjector technology platform for interferons. Thus, an increase in strategic alliances is expected to boost the growth of the interferons market during the forecast period.
Side-effects of autoinjectors is a major challenge to the growth of the global autoinjectors market. Using autoinjectors causes several side effects such as infections, high and low blood pressure, muscle pain, headache, and diarrhea. Patients with chemotherapy-induced anemia show an increased incidence of fatigue, edema, nausea, vomiting, fever, and hypertension. MS patients administered with autoinjectors are vulnerable to severe hepatic injury, including cases of hepatic failure. In certain cases, interferon beta-1 b-filled autoinjectors for such patients can also cause anaphylaxis.
Other allergic reactions may include dyspnea, bronchospasm, tongue edema, skin rash, and urticaria. Thus, the associated side effects can impact the adoption of autoinjectors and encourage patients to opt for alternatives with less severe side effects. Thus, the side effects of autoinjectors are expected to slow down the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is experiencing significant growth driven by advancements in medical technology catering to home care settings. Addressing concerns of safety and accuracy, these devices offer needle free injectors and spring powered autoinjectors, ensuring precise dosage recording and automatic drug reconstitution. With a focus on hormone deficiency, chronic inflammatory disorders, and asthma, health care providers advocate for self-administering solutions in subcutaneous delivery. Enhanced with audio visual cues like LED / LCD based visualization, they accommodate varying drug viscosities and speed of injection, crucial for anaphylactic shock due to food allergens. In empowering patients with chronic conditions, auto injector syringe become indispensable for managing health effectively.
Further, in the evolving landscape of medical technology, autoinjector devices play a pivotal role in patient care, including the administration of urticaria drugs. Evolving from traditional syringes to advanced autoinjectors, these devices accommodate varying drug viscosities critical for treating chronic conditions like urticaria. Designed for self-administration, they provide convenience and precision, empowering patients to effectively manage their health. Safety locks ensure secure usage, boosting user confidence and adherence to treatment protocols. Whether for routine injections or managing complex chronic conditions such as those requiring urticaria drugs, the reliability of autoinjectors simplifies the process and promises improved therapeutic outcomes. As technology continues to advance, autoinjectors are poised to further enhance the delivery and efficacy of urticaria treatments, supporting patient-centric care and treatment adherence.
Autoinjectors Market Scope |
|
Report Coverage |
Details |
Page number |
176 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 36.72% |
Market growth 2024-2028 |
USD 303.65 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
27.0 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, UK, Germany, Canada, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., RAVIMED Sp. zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed Holding AG |
Market dynamics |
Parent market analysis, market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.